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and induced changes in number and activation of tumor-
infiltrating lymphocytes (TILs). In conclusion, our cellular vir-
otherapy shows antitumor activity based on the activation of the
immune system.
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INTRODUCTION: The Na/ I symporter gene (hNIS) is
expressed in the thyroid and allows the accumulation of iodine
from the diet, to form T3 and T4 hormones. Moreover, it is
widely used (i) as a reporter gene for molecular imaging
(when the positron emitter isotope is I124 for PET or Tc99 for
SPECT) or (ii) as a therapeutic gene for cancer therapy, me-
diated by the accumulation of I131. An unresolved challenge
is how to direct this gene specifically to the tumoral area.
Previously, our group demonstrated the migratory capacity of
placental mesenchymal stem cells (MSCs), carrying an
adenovirus-hNIS to tumors, with good results as theragnostic
tool. However, as hNIS is expressed at the placental tissue
(because transfers iodine to the foetus from the maternal
blood), here we decided to study whether placental MSCs and
their exosomes (1) express hNIS endogenously and therefore
transfers the imaging and therapeutic potentials when ad-
ministered with radioactive iodine (2) are capable to reach
tumoral areas when they are intravenously injected due to the
tumoral tissues extravasation. RESULTS/ SUMMARY We
proved that human placenta MSCs and their exosomes have
endogenous expression of NIS, migrate specifically to the
tumour and their endogenous expression of NIS is enough to
image both cells or exosomes in vivo, and their accumulation
caused significant therapeutic effect combined with 131I. This
highlight the use of endogenous NIS expression as therapy but
also to trace new metastatic nodules. FUNDING This work
has been funded by AECC, Universidad Francisco de Vitoria,
ISClll and IACS
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Melanoma is an aggressive type of skin cancer with inci-
dence increasing globally. Surgery is effective in early stage
melanoma, however despite the introduction and widespread
use of check point inhibitors (CPIs), melanoma patients with
distant metastasis only have a 10–30% 5-year survival rate.
Hence, combinations of existing and experimental anti-cancer
agents are being evaluated. ONCOS-102 is an oncolytic ade-
novirus armed with human GM-CSF and an Ad5/3 chimeric
capsid. It has shown to be well tolerated in phase I study
(NCT01598129) wherein it induced antitumor immunity,
infiltration of CD8+ T cells to tumors, and up-regulation of
PD-L1 suggesting that ONCOS-102 could serve as an im-
munosensitizer in combination with CPIs. In-vivo synergism of
these two immune modalities has already been demonstrated.
Now we have evaluated the effect of intra tumoral ONCOS-102
in combination with intra venous pembrolizumab (CPI) on non-
injected lesions in a humanized NOG (hu-NOG) mouse model.
We demonstrated abscopal effect in this model with a dosing
schedule beginning CPI concurrently with ONCOS-102 fol-
lowed by only CPI treatment. In conclusion, the data from this
study further support the therapeutic potential of ONCOS-102
in combination with checkpoint inhibitors for the treatment of
malignant cancer diseases.
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Pretreatment immunoscore and an inflamed
tumour microenvironment are associated with
efficacy in patients with refractory large B cell
lymphoma treated with axicabtagene ciloleucel
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